SHINGRIX Backing Denny Hamlin, Christopher Bell in Combined Four Races

Joe Gibbs Racing will partner with GSK, a pharmaceutical and healthcare company, to feature SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) on board NASCAR Cup Series entries for drivers Denny Hamlin and Christopher Bell throughout the 2023 season.

SHINGRIX, a vaccine that is administered to help protect against shingles, will debut on Denny Hamlin’s No. 11 Toyota Camry TRD Pro in Sunday’s NASCAR Cup Series event at Phoenix Raceway (March 12).

The company will then return to sponsor the 42-year-old driver at Atlanta Motor Speedway (March 19), and Richmond Raceway (April 2). Additionally, SHINGRIX will be featured on Christopher Bell’s No. 20 Toyota Camry TRD Pro at Martinsville Speedway (April 16).

“We are excited to announce our agreement with GSK to feature SHINGRIX,” said Joe Gibbs, owner of Joe Gibbs Racing. “GSK is one of the world’s leading research-based pharmaceutical and healthcare companies prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease.”

Christopher Bell, who finished third place in NASCAR Cup Series point standings last season, has begun his fourth full-time campaign with a pair of top-five results in the first three races. Entering Phoenix, the Norman, Oklahoma-native sits seventh in points.

Meanwhile, Denny Hamlin’s long-tenured quest for his first title in the NASCAR Cup Series has gotten off to a slower start, scoring only one top-10 result in the first three races of the year, at Auto Club. Hamlin enters Phoenix in an impressive sixth-place in points.